From **promotion blocked**.au "Clarity Pharmaceuticals Ltd (ASX: CU6)The Clarity Pharmaceuticals share price is down 21% to $2.80. This appears to have been in response to the pharmaceutical company's half year results, which were released just before the market close on Friday. For the six months ended 31 December, Clarity posted a $23.6 million loss after tax. This is up from a $17.2 million loss a year earlier. Management notes that this reflects an increase in research and development expenditure, which was up $8.9 million to $28.6 million due to an increase in clinical trial activities. Nevertheless, Clarity remains well funded with $111.2 million in cash and term deposits, together with the FY 2024 R&D Tax Incentive receivable of $11 million."
No Way the share price would fall due to R&D cost increase
The stock needs to earn some creditability, looks like this stock does not have strong support from institutions
CU6 Price at posting:
$3.11 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)